Mechanism of decrease of oral bioavailability of cyclosporin a during immunotherapy upon coadministration of amphotericin B

Biopharmaceutics and Drug Disposition

Volumn 29, Issue 4, 2008, Pages 195-203

  Ishizaki, Junko ^a   Ito, Satsuki ^a   Jin, Mingji ^a   Shimada, Tsutomu ^b   Ishigaki, Tamae ^a   Harasawa, Yukiko ^a   Yokogawa, Koichi ^a   Takami, Akiyoshi ^a   Nakao, Shinji ^a   Miyamoto, Ken Ichi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b MUSASHINO UNIVERSITY   (Japan)

Author keywords

Amphotericin B; Cyclosporin A; CYP3A; Drug interaction; Oral bioavailability; P glycoprotein

Indexed keywords

AMINO ACID; AMPHOTERICIN B DEOXYCHOLATE; CYCLOSPORIN A; CYTOCHROME P450 3A2; GLYCOPROTEIN P; HYDROCORTISONE SODIUM SUCCINATE; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; SODIUM CHLORIDE; VITAMIN;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CASE REPORT; CLINICAL OBSERVATION; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MONITORING; DRUG TRANSPORT; DUODENUM; FIRST PASS EFFECT; GENE EXPRESSION; HUMAN; IMMUNOTHERAPY; LIVER; LIVER METABOLISM; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; WISTAR RAT;

ADMINISTRATION, ORAL; AMPHOTERICIN B; ANIMALS; ARYL HYDROCARBON HYDROXYLASES; BIOLOGICAL AVAILABILITY; CYCLOSPORINE; DRUG ANTAGONISM; DUODENUM; ILEUM; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAVENOUS; LIVER; MALE; MEMBRANE PROTEINS; P-GLYCOPROTEIN; P-GLYCOPROTEINS; RATS; RATS, WISTAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 44949242611     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.604     Document Type: Article

References (27)

1. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987; 84: 7735-7738.
2. Georges E, Bradley G, Gariepy J, Ling V. Detection of P-glycoprotein isoforms by gene-specific monoclonal antibodies. Proc Natl Acad Sci USA 1990; 87: 152-156.
3. Gentile DM, Tomlinson ES, Maggs JL, Park BK, Back DJ. Dexamethasone metabolism by human liver in vitro. Metabolite indentification and inhibition of 6-hydroxylation. J Pharmacol Exp Ther 1996; 277: 105-112.
4. Greiner B, Eichelbaum M, Fritz P, et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 1999; 104: 147-153.
5. Nakayama A, Saitoh H, Oda M, Takada M, Aungst BJ. Region-dependent disappearance of vinblastine in rat small intestine and characterization of its P-glycoprotein-mediated efflux system. Eur J Pharm Sci 2000; 11: 317-324.
6. Di Marco MP, Edwards DJ, Wainer IW, Ducharme MP. The effect of grapefruit juice and Seville orange juice on the pharmacokinetics of dextromethorphan: the role of gut CYP3A and P-glycoprotein. Life Sci 2002; 71: 1149-1160.
7. Tamai I, Safa AR. Competitive interaction of cyclosporins with the Vinca alkaloid-binding site of P-glycoprotein in multidrug-resistant cells. J Biol Chem 1990; 265: 16509-16513.
8. Watkins PB. Drug metabolism by cytochromes P450 in the liver and small bowel. Gastroenterol Clin North Am 1992; 21: 511-526.
9. Yokogawa K, Shimada K, Higashi Y, et al. Modulation of mdr1a and CYP3A gene expression in the intestine and liver as possible cause of changes in the cyclosporin A disposition kinetics by dexamethasone. Biochem Pharmacol 2002; 63: 777-783.
10. Shimada T, Aoki Y, Yokogawa K, et al. Influence of cytarabine and cyclophosphamide on the disposition kinetics of cyclosporin A after bone marrow transplantation. Transpl Int 2003; 16: 788-793.
11. Jin M, Shimada T, Shintani M, Yokogawa K, Nomura M, Miyamoto K. Long-term levothyroxine treatment decreases the oral bioavailability of cyclosporin A by inducing P-glycoprotein in small intestine. Drug Metab Pharmacokinet 2005; 20: 324-330.
12. David-Neto E, Ballarati CA, Freitas OJ, et al. Comparison of the fluorescent polarization (TDx) and the enzymatic competitive (EMT 2000) immune assays for the measurement of cyclosporin A blood concentration. Rev Hosp Clin Fac Med Sao Paulo 2000; 55: 207-212.
13. Chin JE, Soffir R, Noonan KE, Choi K, Roninson IB. Structure and expression of the human MDR (P-glycoprotein) gene family. Mol Cell Biol 1989; 9: 3808-3820.
14. Oinonen T, Lindros KO. Hormonal regulation of the zonated expression of cytochrome P-450 3A in rat liver. Biochem J 1995; 309: 55-61.
15. Waki Y, Miyamoto K, Kasugai S, Ohya K. Osteoporosis-like changes in Walker carcinoma 256-bearing rats, not accompanied with hypercalcemia or parathyroid hormone-related protein production. Jpn J Cancer Res 1995; 86: 470-476.
16. Kamataki T, Kitagawa H. Effects of lyophilization and storage of rat liver microsomes on activity of aniline hydroxylase, contents of cytochrome b5 and cytochrome P-450 and aniline-induced P-450 difference spectrum. Jpn J Pharmacol 1974; 24: 195-203.
17. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with Folin phenol reagent. J Biol Chem 1951; 193: 265-275.
18. Laemmli UK. Cleavage of structure proteins during the assembly of the head of bacteriophage T4. Nature London 1970; 227: 680-685.
19. Guengerich FP, Wang P, Davidson NK. Estimation of isozymes of microsomal cytochrome P-450 in rats, rabbits and humans using immunochemical staining coupled with sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Biochemistry 1982; 21: 1698-1706.
20. Yamaoka K, Nakagawa T, Uno T. Statistical moments in pharmacokinetics. J Pharmacokinet Biopharm 1978; 6: 547-558.
21. Hutchaleelaha A, Chow HH, Mayersohn M. Comparative pharmacokinetics and interspecies scaling of amphotericin B in several mammalian species. J Pharm Pharmacol 1997; 49: 178-183.
22. Shibata N, Inoue Y, Fukumoto K, et al. Evaluation of factors to decrease bioavailability of cyclosporin A in rats with gentamicin-induced acute renal failure. Biol Pharm Bull 2004; 27: 384-391.
23. Huang ZH, Murakami T, Okochi A, Yumoto R, Nagai J, Takano M. Expression and function of P-glycoprotein in rats with glycerol-induced acute renal failure. Eur J Pharmacol 2000; 406: 453-460.
24. Leblond FA, Giroux L, Villeneuve JP, Pichette V. Decreased in vivo metabolism of drugs in chronic renal failure. Drug Metab Dispos 2000; 28: 1317-1320.
25. Jin M, Shimada T, Yokogawa K, et al. Contributions of intestinal P-glycoprotein and CYP3A to oral bioavailability of cyclosporin A in mice treated with or without dexamethasone. Int J Pharm 2006; 309: 81-86.
26. Jin M, Shimada T, Yokogawa K, et al. Site-dependent contributions of P-glycoprotein and CYP3A to cyclosporin A absorption, and effect of dexamethasone in small intestine of mice. Biochem Pharmacol 2006; 72: 1042-1050.
27. Shimada T, Terada A, Yokogawa K, et al. Lowered blood concentration of tacrolimus and its recovery with changes in expression of CYP3A and P-glycoprotein after high-dose steroid therapy. Transplantation 2002; 74: 1419-1424.